CPMC - MISSION BERNAL CAMPUS
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $3.7M
- Transactions
- 297
- Companies
- 27
- Average per transaction
- $12,382
Who reported the payments
| Eisai Inc. | $657,536 |
| Edwards Lifesciences | $637,037 |
| E.r. Squibb & Sons, L.L.C. | $625,526 |
| Pfizer | $482,368 |
| Novartis | $456,254 |
| Genentech, Inc. | $317,552 |
| Biogen | $215,253 |
| Sanofi Pasteur Inc. | $72,565 |
| CSL Behring | $54,053 |
| Intercept Pharma Europe Ltd. | $43,870 |
| Argenx US, Inc. | $17,157 |
| Incyte Corporation | $15,835 |
| AstraZeneca | $13,573 |
| Mirati Therapeutics, Inc. | $12,974 |
| Biotronik Inc. | $11,800 |
| F. Hoffmann-la Roche AG | $10,750 |
| SK Life Science, Inc. | $10,509 |
| Morphosys AG | $7,050 |
| Bristol Myers Squibb | $3,750 |
| Genentech USA, Inc. | $3,000 |
| Roche Products Limited | $2,813 |
| Adaptive Biotechnologies Corporation | $2,500 |
| Array Biopharma Inc | $1,400 |
| Stryker | $1,152 |
| Zimmer Biomet | $650 |
| Neuropace, Inc. | $430 |
| Genmark Diagnostics, Inc. | $113 |